Список литературы

1. Козлова А.Л., Мамзерова Е.С., Новичкова Г.А., Щербина А.Ю. Клинические проявления и терапия криопирин-ассоциированных периодических синдромов. Вопросы гематологии/ онкологии и иммунопатологии в педиатрии, 2014; 13:42-48.

2. Fietta P. Autoinflammatory diseases: the hereditary periodic fever syndromes. Acta Biomed. 2004;75(2):92-99.

3. Gattorno M. Данные конгресса PRES2018 (Pediatric Rheumatology European Society), 5-8 September 2018.

4. Ярилин А.А. Иммунология. — М.: ГЭОТАР-Медиа, 2010.

5. Хаитов, Р.М. Иммунология: структура и функции иммунной системы: учеб. пособие / Р.М. Хаитов. - М.: ГОЭТАР-Медиа, 2014. - 280 с.

6. Kato H, Oh SW, Fujita T. RIG-I-Like Receptors and Type I Interferonopathies. J Interferon Cytokine Res. 2017 May;37(5):207-213.

7. Хаитов, Р.М. Иммунология: атлас / Р.М. Хаитов, А.А. Ярилин, Б.В. Пинегин. - М.: ГОЭТАР-Медиа, 2011. - 324 с.

8. Zevini A, Olagnier D, Hiscottl J. Cross-Talk between the Cytoplasmic RIG-I and STING Sensing Pathways // Trends Immunol. 2017 Mar; 38(3): 194-205.

9. Miner JJ, Diamond MS. MDA5 and autoimmune disease // Nat Genet. 2014 May; 46(5): 418-419.

10. Crow YJ, Chase DS, Lowenstein Schmidt J, Szynkiewicz M et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1 // Am J Med Genet A. 2015;2015;167A:296-312.

11. Crow YJ, Hayward BE, Parmar R, Robins P. Leitch A et al. Mutations in the gene encoding the 3-5 DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat. Genet. 2006;38:917-920.

12. Chowdhury D, Beresford PJ, Zhu P, Zhang D, Sung JS, Demple B, Perrino FW, Lieberman J. The exonuclease TREX1 is in the SET complex and actsin concert with Nm23-H1 to degrade DNA during granzyme A-mediated cell death. Mol. Cell. 2006; 23: 133-142.

13. Yang YG, Lindahl T, Barnes DE. TREX1 exonuclease degrades ssDNA to prevent chronic checkpointactivation and autoimmune disease. Cell. 2007; 131: 873-886.

14. Stetson DB, Ko JS, Heidmann T, Medzhitov R. TREX1 prevents cell-intrinsic initiation of autoimmunity. Cell. 2008; 134: 587-598.

15. Reijns MA, Rabe B, Rigby RE, Mill P, Astell KR, Lettice LA, Boyle S, Leitch A, Keighren M, Kilanowski F, Devenney PS, Sexton D, Grimes G, Holt IJ, Hill RE, Taylor MS, Lawson KA, Dorin JR, Jackson AP. Enzymatic removal of ribonucleotides from DNA is essential for mammalian genome integrity and development. Cell. 2012; 149: 1008-1022.

16. Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW et al. Mutations involved in Aicardi-Goutieres syndrome implicate SAM HD1 as regulator of the innate immune response. Nat. Genet. 2009; 41: 829-832.

17. Kretschmer S, Wolf C, Konig N, Staroske W, Guck J et al. SAMHD1 prevents autoimmunity by maintaining genome stability. Ann. Rheum. Dis. 2014; 74 (3): e17.

18. Liddicoat BJ, Piskol R, Chalk AM, Ramaswami G, Higuchi M, Hartner JC, Li JB, Seeburg PH, Walkley CR. RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself. Science. 2015; 349 (6252): 1115-1120.

19. Rice GI, Del Toro DY, Jenkinson EM, Forte GM, Anderson BH, Ariaudo G et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat. Genet. 2014; 46: 503-509.

20. The American Journal of Human Genetics 96, 266-274, February 5, 2015 267 Mutations in DDX58, which Encodes RIG-I,Cause Atypical Singleton-Merten Syndrome Mi-Ae Jang,1,16 Eun Kyoung Kim,2,16 Hesung Now,3 Nhung T.H. Nguyen,3 Woo-Jong Kim,3 Joo-Yeon Yoo,3 Jinhyuk Lee,4,5 Yun-Mi Jeong,6

21. Solis M, Nakhaei P, Jalalirad M, Lacoste J, Douville R, Arguello M, Zhao T, Laughrea M, Wainberg MA, Hiscott J (Feb 2011). "RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I". Journal of Virology. 85 (3): 1224-36.

22. Hou F, Sun L, Zheng H, Skaug B, Jiang QX, Chen ZJ (Aug 2011). "MAVS forms functional prionlike aggregates to activate and propagate antiviral innate immune response". Cell. 146 (3): 44861.

23. Федоров Е.С. Протеасомные болезни - новый раздел аутовоспалительной патологии. Современная ревматология. 2013;(4):38-46.

24. Amelia McDermottl, MA,.Jennifer Jacks2, MD, Marcus Kessler3, MD, Peter D. Emanuel4, MD, and Ling Gao5, MD, PhD Proteasome-associated autoinflammatory syndromes: advances in pathogeneses, clinical presentations, diagnosis, and management.

25. Kim H, Sanchez GA2, Goldbach-Mansky R Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus. J Mol Med (Berl). 2016 Oct;94(10):1111-1127. Epub 2016 Sep 27.

26. Kretschmer S, Lee-Kirsch MA. Type I interferon-mediated autoinflammation and autoimmunity. Curr Opin Immunol. 2017 Dec;49:96-102. doi: 10.1016/j.coi.2017.09.003.

27. Stefano Volpi, Paolo Picco, Roberta Caorsi, Fabio Candotti and Marco Gattorno. Type I interferonopathies in pediatric rheumatology. Pediatr Rheumatol Online J. 2016 Jun 4;14(1):35. doi: 10.1186/s12969-016-0094-4.

2 8. Torrelo A. CANDLE Syndrome As a Paradigm of Proteasome- Related Autoinflammation. Front. Immunol. 8:927. doi: 10.3389/fimmu.2017.00927

29. Torrelo A, Patel S, Colmenero I, Gurbindo D, Lendinez F, Hernandez A, Lopez-Robledillo JC, Dadban A, Requena L, Paller AS. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome. J. Am. Acad. Dermatol. 2010; 62: 489-495.

30. Arima K, Kinoshita A, Mishima H, Kanazawa N, Kaneko T,Mizushima T et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc. Natl. Acad. Sci. USA. 2011; 108: 14914-14919.

31. Kitamura A, Maekawa Y, Uehara H, Izumi K, Kawachi I,Nishizawa M, Toyoshima Y et al. A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy inhumans. J. Clin. Invest. 2011; 121: 4150-4160.

32. Liu Y, Ramot Y, Torrelo A, Paller AS, Si N, Babay S, Kim PW, Sheikh A, Lee CC et al. Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheumatism. 2012; 64: 895-907.

33. Cavalcante MP, Brunelli JB, Miranda CC, Novak GV, Malle L,Aikawa NE, Jesus AA, Silva CA. CANDLE syndrome: chronic atypical neutrophilic dermatosis with lipodystrophy andelevated temperature-a rare case with a novel mutation. Eur. J. Pediatr. 2016; 175: 735-740.

34. Brehm A, Liu Y, Sheikh A, Marrero B, Omoyinmi E, Zhou Q,Montealegre G, Biancotto A et al. Additive loss-of-function proteasome subunit mutationsin CANDLE/PRAAS patients promote type I IFN production. J. Clin. Invest. 2015; 125: 4196-4211.

35. Brehm, A., Liu, Y., Sheikh, A., Marrero, B., Omoyinmi, E., Zhou, Q., Montealegre, G., Biancotto, A., Reinhardt, A., Almeida de Jesus, A., Pelletier, M., Tsai, W. L., and 31 others. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J. Clin. Invest. 125: 4196-4211, 2015. Note: Erratum: J. Clin. Invest. 126: 795 only, 2016.

36. Poli, M. C., Ebstein, F., Nicholas, S. K., de Guzman, M. M., Forbes, L. R., Chinn, I. K., Mace, E. M., Vogel, T. P., Carisey, A. F., Benavides, F., Coban-Akdemir, Z. H., Gibbs, R. A., and 16 others. Heterozygous truncating variants in POMP escape nonsense-mediated decay and cause a unique immune dysregulatory syndrome. Am. J. Hum. Genet. 102: 1126-1142, 2018.

37. Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Montealegre Sanchez GA, Tenbrock K, Wittkowski H, Jones OY, Kuehn HS, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014; 371:507-518.

38. Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg MC, Goudin N, Fremond ML, Nitschke P, Molina TJ, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest. 2014; 124:5516-5520.

39. Omoyinmi E, Melo Gomes S, Nanthapisal S, Woo P, Standing A, Eleftheriou D, Klein N, Brogan PA. Stimulator of interferon genes-associated vasculitis of infancy. Arthritis Rheumatol. 2015; 67:808.

40. Munoz J, Rodiere M, Jeremiah N, Rieux-Laucat F, Oojageer A, Rice GI, Rozenberg F, Crow YJ, Bessis D. Stimulator of interferon genes-associated vasculopathy with onset in infancy: a mimic of childhood Granulomatosis with Polyangiitis. JAMA Dermatol. 2015; 151:872-877.

41. Chia J, Eroglu FK, Ozen S, Orhan D, Montealegre-Sanchez G, de Jesus AA, Goldbach-Mansky R, Cowen EW. Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy. J Am Acad Dermatol. 2016; 74:186-189.

42. Burdette DL, Vance RE. STING and the innate immune response to nucleic acids in the cytosol. Nat Immunol. 2013; 14:19-26.

43. Keating SE, Baran M, Bowie AG. Cytosolic DNA sensors regulating type I interferon induction. Trends Immunol. 2011; 32:574-581.

44. Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Montealegre Sanchez GA, Tenbrock K, Wittkowski H, Jones OY, Kuehn HS, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014; 371:507-518.

45. Briggs TA, Rice GI, Daly S, Urquhart J et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat. Genet. 2011;43:127-131.

46. Lausch E, Janecke A, Bros M, Trojandt S, Alanay Y et al. Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity. Nat. Genet. 2011; 43: 132-137.